Biocon Limited completed a significant corporate action involving the acquisition of remaining equity shares in its material subsidiary, Biocon Biologics Limited (BBL), and a corresponding preferential share issuance.
Key Transaction Details
- Completion Date: June 29, 2026
- Transaction Type: Share swap acquisition
- BBL Shares Acquired: 1,15,36,956 equity shares
- Selling Shareholders: 127 shareholders of BBL
- Consideration: 87,86,362 equity shares of Biocon Limited allotted on preferential basis
- Issue Price: ₹376.41 per equity share
- Face Value: ₹5 per share
- Share Status: Fully paid-up, dematerialized form
Regulatory Approvals
- Shareholder approval obtained via postal ballot on June 7, 2026
- In-principle approval from NSE and BSE dated June 24, 2026
- Execution approved by Preferential Issue & Allotment Committee of Biocon Limited
Capital Structure Impact
- Pre-transaction capital: ₹8,10,45,38,865 comprising 1,62,09,07,773 equity shares
- Post-transaction capital: ₹8,14,84,70,675 comprising 1,62,96,94,135 equity shares
- Capital increase: ₹4,39,31,810
- Dilution: Approximately 5.42% increase in outstanding shares
Subsidiary Status Change
Biocon Biologics Limited became a wholly-owned subsidiary of Biocon Limited effective June 29, 2026, following the acquisition of all remaining outstanding shares.
Committee Proceedings
The Preferential Issue & Allotment Committee meeting commenced at 10:00 PM and concluded at 10:10 PM on June 29, 2026.
Additional Information
The newly allotted equity shares will rank pari-passu with existing equity shares of the company. The transaction was executed pursuant to share purchase agreements with the allottees.
Annexure Details
The annexure provides complete details of all 127 allottees showing the number of BBL shares acquired from each shareholder and the corresponding number of Biocon shares allotted to each as consideration.
#Biocon #BioconBiologics #M&A #PreferentialAllotment #SEBIDisclosure #RegulatoryCompliance #CorporateAction #Neutral